Johnson & Johnson

JOHNSON & Johnson said on Monday (Jun 8) it will acquire biotech Firefly Bio for US$1 billion in cash, as it looks to expand its cancer drug pipeline.

The upbeat performance comes as the company faces multiple challenges, including tariff uncertainty on its medical devices unit

[NEW YORK] Johnson & Johnson has agreed to buy the cancer treatment biotech Halda Therapeutics for US$3.05 billion cash, part of a strategy to cope with eroding sales for its major psoriasis drug.

[LONDON] Johnson & Johnson is facing the first lawsuits in Britain over allegations that its talc products cause cancer, as it fights tens of thousands of similar claims in the United States.

[NEW YORK] Johnson & Johnson (J&J) said on Thursday (Aug 21) it would invest US$2 billion in North Carolina as it aims to expand its US manufacturing presence amid looming drug import duties proposed ...

[NEW YORK] A US bankruptcy judge on Monday rejected Johnson & Johnson’s US$10 billion proposal to end lawsuits alleging that its baby powder and other talc products cause ovarian cancer, marking the t...

JOHNSON & Johnson (J&J) is in talks to acquire Intra-Cellular Therapies, a biopharmaceutical company focused on treatments for central nervous system disorders, sources familiar with the matter said.

A JOHNSON & Johnson (J&J) subsidiary can pursue its third attempt to resolve tens of thousands of lawsuits alleging its talc products caused cancer in a federal bankruptcy court in Texas, a judge rule...

JOHNSON & Johnson plans to pay an additional US$1.1 billion to resolve tens of thousands of legal actions alleging its baby powder and other talc products caused cancer, two people familiar with the m...